[HTML][HTML] Chitosan in non-viral gene delivery: Role of structure, characterization methods, and insights in cancer and rare diseases therapies

B Santos-Carballal, E Fernández Fernández… - Polymers, 2018 - mdpi.com
Non-viral gene delivery vectors have lagged far behind viral ones in the current pipeline of
clinical trials of gene therapy nanomedicines. Even when non-viral nanovectors pose less …

[HTML][HTML] Protein kinase CK2: Intricate relationships within regulatory cellular networks

T Nuñez de Villavicencio-Diaz, AJ Rabalski… - Pharmaceuticals, 2017 - mdpi.com
Protein kinase CK2 is a small family of protein kinases that has been implicated in an
expanding array of biological processes. While it is widely accepted that CK2 is a regulatory …

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

DD Stefano, VR Villella, S Esposito, A Tosco, A Sepe… - Autophagy, 2014 - Taylor & Francis
Restoration of BECN1/Beclin 1-dependent autophagy and depletion of SQSTM1/p62 by
genetic manipulation or autophagy-stimulatory proteostasis regulators, such as cystamine …

CFTR structure and cystic fibrosis

N Cant, N Pollock, RC Ford - The international journal of biochemistry & …, 2014 - Elsevier
CFTR (cystic fibrosis transmembrane conductance regulator) is a member of the ATP-
binding cassette family of membrane proteins. Although almost all members of this family …

[HTML][HTML] LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate

E Belluzzi, A Gonnelli, MD Cirnaru, A Marte… - Molecular …, 2016 - Springer
Background Lrrk2, a gene linked to Parkinson's disease, encodes a large scaffolding protein
with kinase and GTPase activities implicated in vesicle and cytoskeletal-related processes …

Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma

T Purzner, J Purzner, T Buckstaff, G Cozza… - Science …, 2018 - science.org
A major limitation of targeted cancer therapy is the rapid emergence of drug resistance,
which often arises through mutations at or downstream of the drug target or through intrinsic …

[HTML][HTML] A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

A Tosco, F De Gregorio, S Esposito… - Cell Death & …, 2016 - nature.com
We previously reported that the combination of two safe proteostasis regulators, cysteamine
and epigallocatechin gallate (EGCG), can be used to improve deficient expression of the …

[HTML][HTML] Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation

E Ferrari, R Monzani, VR Villella, S Esposito… - Cell death & …, 2018 - nature.com
Cystic fibrosis (CF), the most common lethal monogenic disease in Caucasians, is
characterized by recurrent bacterial infections and colonization, mainly by Pseudomonas …

[HTML][HTML] Dysfunctional inflammation in cystic fibrosis airways: from mechanisms to novel therapeutic approaches

A Ghigo, G Prono, E Riccardi, V De Rose - International Journal of …, 2021 - mdpi.com
Cystic fibrosis (CF) is an inherited disorder caused by mutations in the gene encoding for the
cystic fibrosis transmembrane conductance regulator (CFTR) protein, an ATP-gated chloride …

[HTML][HTML] Peripheral protein quality control as a novel drug target for CFTR stabilizer

R Fukuda, T Okiyoneda - Frontiers in Pharmacology, 2018 - frontiersin.org
Conformationally defective cystic fibrosis transmembrane conductance regulator (CFTR)
including rescued ΔF508-CFTR is rapidly eliminated from the plasma membrane (PM) even …